Results 1 to 10 of about 783,471 (282)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network [PDF]

Pharmaceutics, 2021
The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug–drug interaction (DDI) studies.
Fatima Zahra Marok, Laura Maria Fuhr, Nina Hanke, Dominik Selzer, Thorsten Lehr   +4 more
doaj   +7 more sources

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy [PDF]

Pharmacogenomics and Personalized Medicine, 2022
Sandro Salamone,1 Sara Spirito,2 Maurizio Simmaco,2 Marius Unger,1 Saskia Preissner,3 Björn-Oliver Gohlke,1 Andreas Eckert,1 Robert Preissner1 1Science-IT and Institute of Physiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie ...
Salamone S, Spirito S, Simmaco M, Unger M, Preissner S, Gohlke BO, Eckert A, Preissner R   +7 more
doaj   +15 more sources

Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative [PDF]

Journal of Personalized Medicine, 2020
We explored the association between CYP2C19/3A4 mediated drug-gene-interaction (DGI), drug-drug-interaction (DDI) and drug-drug-gene-interaction (DDGI) and (es)citalopram dispensing course.
Muh Akbar Bahar, Pauline Lanting, Jens H J Bos   +2 more
exaly   +8 more sources

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2023
The immunosuppressant and narrow therapeutic index drug tacrolimus is metabolized mainly via cytochrome P450 (CYP) 3A4 and CYP3A5. For its pharmacokinetics (PK), high inter‐ and intra‐individual variability can be observed.
Helena Leonie Hanae Loer, Denise Feick, Simeon Rüdesheim, Dominik Selzer, Matthias Schwab, Donato Teutonico, Sebastian Frechen, Maaike van derLee, Dirk Jan A. R. Moes, Jesse J. Swen, Thorsten Lehr   +10 more
doaj   +5 more sources

Hyponatremic Cognitive Dysfunction Resulting from Drug-Drug-Gene Interaction between Sertraline and Cannabidiol in an Intermediate CYP2C19 Metabolizer Patient [PDF]

INNOVATIONS in Pharmacy, 2022
Background: Pharmacogenomics (PGx) can provide more precision in determining causation of adverse drug reactions (ADRs) from drug-drug-gene interaction clinical application.
Jade Nanan, Sheena Crosby, Michael J. Schuh   +2 more
doaj   +4 more sources

A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions [PDF]

Pharmaceutics, 2020
Trimethoprim is a frequently-prescribed antibiotic and therefore likely to be co-administered with other medications, but it is also a potent inhibitor of multidrug and toxin extrusion protein (MATE) and a weak inhibitor of cytochrome P450 (CYP) 2C8. The
Denise Türk, Nina Hanke, Thorsten Lehr
doaj   +5 more sources

Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling [PDF]

Pharmaceutics, 2022
Clomiphene, a selective estrogen receptor modulator (SERM), has been used for the treatment of anovulation for more than 50 years. However, since (E)-clomiphene ((E)-Clom) and its metabolites are eliminated primarily via Cytochrome P450 (CYP) 2D6 and ...
Christina Kovar, Lukas Kovar, Simeon Rüdesheim, Dominik Selzer, Boian Ganchev, Patrick Kröner, Svitlana Igel, Reinhold Kerb, Elke Schaeffeler, Thomas E. Mürdter, Matthias Schwab, Thorsten Lehr   +11 more
doaj   +4 more sources

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions [PDF]

Pharmaceuticals, 2021
Drug interactions are a well-known cause of adverse drug events, and drug interaction databases can help the clinician to recognize and avoid such interactions and their adverse events. However, not every interaction leads to an adverse drug event.
Martina Hahn, Sibylle C. Roll
doaj   +6 more sources

A physiologically‐based pharmacokinetic/pharmacodynamic modeling approach for drug–drug‐gene interaction evaluation of S‐warfarin with fluconazole [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Warfarin is a widely used anticoagulant, and its S‐enantiomer has higher potency compared to the R‐enantiomer. S‐warfarin is mainly metabolized by cytochrome P450 (CYP) 2C9, and its pharmacological target is vitamin K epoxide reductase complex subunit 1 (
Kuo Geng, Chaozhuang Shen, Xiaohu Wang, Xingwen Wang, Wenxin Shao, Wenhui Wang, Tao Chen, Hua Sun, Haitang Xie   +8 more
doaj   +4 more sources

Associations between antihypertensive drug-related gene polymorphisms and cardiovascular outcomes in hypertensive patients: a gene-drug interaction study [PDF]

Scientific Reports
Antihypertensive therapy is pivotal in preventing cardiovascular events, yet treatment efficacy varies significantly among individuals due to genetic polymorphisms.This study aimed to investigate the association between specific antihypertensive drug ...
Zetong Li, Huixia Liu, Mengshi Chen, Jing Deng, Ziyu Ma, Ge Huang, Cheng Li, Meng Su, Hua Zhong   +8 more
doaj   +2 more sources